Newly Designated NCI Director Roundly Applauded by Cancer Community

Publication
Article
OncologyONCOLOGY Vol 16 No 2
Volume 16
Issue 2

The cancer community is expressing unanimous approval of President George W. Bush’s appointment of Andrew von Eschenbach, MD, as director of the National Cancer Institute (NCI). Dr. von Eschenbach was director of the Genitourinary Cancer Center and Prostate Cancer Research Program at the University of Texas M. D. Anderson Cancer Center. "[His] extensive experience in cancer research, treatment, and prevention has prepared him extraordinarily well to head the NCI," said Larry Norton, MD, president of the American Society of Clinical Oncology. "As both a recognized leader in the oncology community and as a cancer survivor, Andy brings a distinctive perspective to this position."

The cancer community is expressing unanimous approvalof President George W. Bush’s appointment of Andrew von Eschenbach, MD, asdirector of the National Cancer Institute (NCI). Dr. von Eschenbach was directorof the Genitourinary Cancer Center and Prostate Cancer Research Program at theUniversity of Texas M. D. Anderson Cancer Center. "[His] extensiveexperience in cancer research, treatment, and prevention has prepared himextraordinarily well to head the NCI," said Larry Norton, MD, president ofthe American Society of Clinical Oncology. "As both a recognized leader inthe oncology community and as a cancer survivor, Andy brings a distinctiveperspective to this position."

Dr. Von Eschenbach has also been active in the American Cancer Society (ACS).He served recently as president-elect of the ACS’s national volunteer Board ofDirectors. John R. Seffrin, the ACS’s national chief executive officer, said,"As the chair of our cancer control committee and numerous other postswithin the Society throughout the years, Dr. von Eschenbach has proven hiscompassion and commitment to eradicating cancer as a major health threat hereand now. The National Cancer Institute will do well by his leadership andpassion."

Recent Videos
Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.
Two experts are featured in this series.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
4 experts are featured in this series.
Based on a patient’s SCLC subtype, and Schlafen 11 status, patients will be randomly assigned to receive durvalumab alone or with a targeted therapy in the S2409 PRISM trial.
4 experts are featured in this series.
Daniel Peters, MD, aims to reduce the toxicity associated with AML treatments while also improving therapeutic outcomes.
Numerous clinical trials vindicating the addition of immunotherapy to first-line chemotherapy in SCLC have emerged over the last several years.
Patients with AML will experience different toxicities based on the treatment they receive, whether it is intensive chemotherapy or targeted therapy.
A younger patient with AML who is more fit may be eligible for different treatments than an older patient with chronic medical conditions.
Related Content